Translocation between the immunoglobulin heavy chain locus, IGH on chromosome 14 with the NSD2 locus (also known as MMSET or WHSC1) on chromosome 4, leads to NSD2 overexpression in 15–20% of multiple myeloma (MM) patients that have a poor survival rate and do not respond well to cytotoxic chemotherapy21–24. This evidence concerns the gene NSD2 and Miyoshi myopathy.